Search

Your search keyword '"Godfried MH"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Godfried MH" Remove constraint Author: "Godfried MH"
72 results on '"Godfried MH"'

Search Results

1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.

2. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

3. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009

4. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

6. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

7. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

8. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery

9. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe

10. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

11. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

12. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe

13. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

14. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

15. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

16. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

17. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West

18. Nelfinavir and nevirapine side effects during pregnancy

19. Krachtige antiretrovirale therapie (HAART) bij HIV-positieve zwangeren in Nederland, 1997-2003: veilig, effectief en met weinig bijwerkingen

23. Levels and patterns of HIV RNA viral load in untreated pregnant women

24. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

25. Patient participation in the medical specialist encounter: does physicians' patient-centred communication matter?

26. Determinants of physicians' patient-centred behaviour in the medical specialist encounter.

27. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

28. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

29. Registration of catheter-related complications in adverse events reporting systems: a major underestimation of the real complication practice.

30. De-implementation strategy to reduce inappropriate use of intravenous and urinary catheters (RICAT): a multicentre, prospective, interrupted time-series and before and after study.

31. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age.

32. In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants: author's reply.

33. De-implementation strategy to Reduce the Inappropriate use of urinary and intravenous CATheters: study protocol for the RICAT-study.

34. Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women.

35. In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.

36. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls.

37. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.

38. Transplacental passage of nevirapine, nelfinavir and lopinavir.

39. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe.

40. A woman with a painful hip.

41. [Treatment of HIV-infected pregnant women: prevention of virus transmission and adverse effects in mother and child].

42. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery.

43. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.

44. [Severe psychosis in an African woman due to the antiretroviral agent efavirenz].

45. Nelfinavir and nevirapine side effects during pregnancy.

46. A neonate with macrosomia, cardiomyopathy and hepatomegaly born to an HIV-infected mother.

47. Satisfaction with the outpatient encounter: a comparison of patients' and physicians' views.

48. [Treatment of HIV-1 infected pregnant women].

49. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].

50. Nelfinavir plasma concentrations are low during pregnancy.

Catalog

Books, media, physical & digital resources